Regentis Biomaterials Ltd. (NYSE:RGNT) — Market Cap & Net Worth
Market Cap & Net Worth: Regentis Biomaterials Ltd. (RGNT)
Regentis Biomaterials Ltd. (NYSE:RGNT) has a market capitalization of $11.24 Million ($11.24 Million) as of October 11, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #26774 globally and #5553 in its home market, demonstrating a -12.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regentis Biomaterials Ltd.'s stock price $1.60 by its total outstanding shares 7023921 (7.02 Million).
Regentis Biomaterials Ltd. Market Cap History: 2026 to 2026
Regentis Biomaterials Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $11.24 Million to $11.24 Million (0.00% CAGR). Check RGNT stock price for real-time trading data and today's change.
Regentis Biomaterials Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regentis Biomaterials Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Regentis Biomaterials Ltd. cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RGNT by Market Capitalization
Companies near Regentis Biomaterials Ltd. in the global market cap rankings as of October 11, 2026. See RGNT net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Regentis Biomaterials Ltd. by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #178 globally with a market cap of $132.26 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #343 globally with a market cap of $79.23 Billion USD ( €67.77 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #425 globally with a market cap of $67.43 Billion USD ( €57.68 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #549 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #178 | Intuitive Surgical Inc | NASDAQ:ISRG | $132.26 Billion | $423.96 |
| #343 | EssilorLuxottica S. A. | PA:EL | $79.23 Billion | €146.35 |
| #425 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $67.43 Billion | €71.00 |
| #549 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Regentis Biomaterials Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, Regentis Biomaterials Ltd.'s market cap moved from $11.24 Million to $ 11.24 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.24 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Regentis Biomaterials Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.24 Million USD |
| MoneyControl | $11.24 Million USD |
| MarketWatch | $11.24 Million USD |
| marketcap.company | $11.24 Million USD |
| Reuters | $11.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical tr… Read more